Kornimate/medical-research-clean huggingface dataset:
evolution of intestinal microbiota in patients with juvenile spondylarthropathy according to typology of treatment

Conditions: Spondylarthropathies

Summary: idiopathic juvenile arthritis includes 20% of patients with arthritis with enthesitis or juvenile spondyloarthropathy. this is treated with anti-inflammatory drugs and then followed by biotherapy with dmards (drugs modifying the activity of rheumatic disease) if the former are insufficient. methotrexate (mtx) may also be used before these biotherapies. recently, in adults, a particular profile of intestinal microbiota has been shown to alter the availability of mtx making it in efficient. knowing that pediatric patients with juvenile spondyloarthropathy have an imbalance of their intestinal flora (dysbiosis) the investigators wanted to explore whether dmards could have a similar impact on the microbiota of these young patients and alter the response to treatment.


Eligibility criteria:
inclusion criteria: * patients aged over 8 and under 17 years old (included). * patients diagnosed with arthritis with juvenile enthesitis according to the international league of associations for rheumatology (ilar) criteria. * patients who haven't been treated by methotrexate or biotherapy for at least 3 months. * patients who haven't been treated by cortisone for over a month. * patients whose parents have given written informed consent. * patients for whom the consent form has been signed by their legal guardian. * patients covered by the social security system or benefitting from private health insurance. exclusion criteria: * patients enrolled in another category 1 study or who have already taken part in a category 1 study within 3 months prior to inclusion. * patients who are within an exclusion period determined by another study.

Keywords: microbiota
eye patch therapy for central serous retinopathy (csr)

Conditions: Central Serous Retinopathy (CSR)

Summary: first, this study will investigate the viability of 24-hour eye patching as a potential treatment modality for csr. second, this study will assess a potential physiologic explanation for csr, namely if inhibition of photic stimulation of the diseased retina will aid in ameliorating disease severity and disease duration.


Eligibility criteria:
inclusion criteria: * adults 18 years of age and older * both males and females * patients diagnosed with active central serous retinopathy * patients who are willing to use an eye patch in the affected eye for 24 hours * patients who are able to make the follow up appointments as required by the study exclusion criteria: * individuals under 18 years of age * patients with vision less than 20/40 in the unaffected eye. * patients who are not able to undergo mferg testing in a realiable manner.
outcome measures of pulsed radiofrequency of the genicular nerves when performed with and without concomitant local corticosteroid administration

Conditions: Knee Pain Chronic

Summary: a single blinded randomized controlled trial to compare outcomes of patients with chronic knee pain receiving radiofrequency with or without corticosteroids.


Eligibility criteria:
inclusion criteria: * men and women with pain secondary to osteoarthritis of the knee * age of 18 years and up * fits criteria for procedure of genicular nerve block and pulsed radiofrequency neuromodulation exclusion criteria: * patients who are incapable of judgment and/or to give informed consent * patients who are pregnant * patients who are under 18 years old * patients who have allergies to local anesthetic * patients with platelet dysfunction or bleeding disorders * patients who are currently mentally unstable * patients who have a diagnosis of fibromyalgia
the relationship between maximal oxygen consumption and inspiratory muscle activation pattern under loaded inspiratory muscle tests in healthy adults

Conditions: Healthy

Summary: maximal oxygen consumption, vo2max, is the gold standard to evaluate human aerobic fitness, which stands for the maximal capacity of cardiorespiratory system and musculoskeletal system to transport and utilize oxygen. previous study showed that there is significant correlation between maximal oxygen consumption from cardiopulmonary exercise test and strength and endurance of lower extremities. in people with sedentary lifestyle, they often limited by the lower limb muscle performance during cardiopulmonary exercise test. their breathing patterns are more irregular than athletes during cardiopulmonary exercise test. however, there is no study comparing the activation pattern of respiratory muscles between these two groups. whether the breathing pattern in people with lower exercise capacity is less efficient under exertional activities still unknown. the purpose of this study is to investigate the relationship between maximal oxygen consumption and inspiratory muscle activation pattern in healthy adults.


Eligibility criteria:
inclusion criteria: * healthy adults (age \> 20 years old) * be able to cooperate with the measurements of this study exclusion criteria: * any clinical diagnosis that will influence the measurement, including any history of neuromyopathy * angina, acute myocardial infarction in the previous one month * pregnancy * history of syncope during exercise * any musculoskeletal system disorder that unable to perform cardiopulmonary exercise test
high intensity laser vs instrument-assisted soft tissue mobilization on trapezius myofascial pain syndrome

Conditions: High Intensity Laser; Instrument Assisted Soft Tissue Mobilization; Trapezius Muscle Strain; Myofascial Pain Syndrome

Summary: the purpose of the study was to 1. investigate the effect of high-intensity laser therapy versus instrument-assisted soft tissue mobilization on pain level in patients with myofascial pain syndrome of upper trapezius muscle. 2. investigate the effect of high intensity laser therapy versus instrument-assisted soft tissue mobilization on rom in patients with myofascial pain syndrome of upper trapezius muscle

myofascial pain syndrome is a common musculoskeletal pain affecting 30% of patients in primary care. it is characterized by trigger points in the upper trapezius muscle, which is linked to neck and shoulder pain. non-invasive treatments like exercises, manipulation, and physical agents have been suggested for managing neck pain. laser therapy, including low-level and high-intensity, has been found effective in reducing pain intensity and improving functional activity. instrument-assisted soft tissue mobilization is another technique used to treat myofascial pain syndrome. instrument-assisted soft tissue mobilization stimulates connective tissue remodeling, resorbing excessive fibrosis, and promoting collagen repair and regeneration. the study aims to investigate the effect of high intensity laser therapy versus instrument-assisted soft tissue mobilization in treating myofascial pain syndrome of the upper trapezius muscle.

Eligibility criteria:
inclusion criteria: 1. the patient age ranged from 20 to 50 years 2. presence of myofascial trigger points in the upper trapezius muscle 3. having neck discomfort symptoms that were triggered by certain neck positions and by palpating the cervical musculature for at least three months 4. patient willing and able to participate in an exercise program safely exclusion criteria: 1. medical red flag history (such as tumour, fracture, metabolic diseases, rheumatoid arthritis and osteoporosis) 2. neck pain with cervical radiculopathy or neck pain associated with externalized cervical disc herniation. 3. if the patient had previous surgery in the neck area (irrespective of the reason for the operation) 4. neck pain accompanied by vertigo caused by vertebra basilar insufficiency or accompanied by non-cervicogenic headaches
radiotherapy or surgery combined with intense androgen deprivation therapy for mcrpc

Conditions: Prostate Cancer Metastatic Disease

Summary: this multi-center randomized controlled phase ii trial was carried out in several hospitals in china to evaluate the efficacy and safety of radiotherapy or radical prostatectomy combined with intense androgen deprivation therapy for newly diagnosed metastatic prostate cancer.


Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed prostate adenocarcinoma, with distant metastasis diagnosed by novel imaging modalities (psma pet/ct or psma pet/mr), involving ≤10 metastatic sites (amenable to local therapy) and without visceral metastasis. 2. the primary lesion is deemed resectable, or can achieve a resectable state following iadt. 3. non-castration range (≥50 ng/dl), or the duration of testosterone levels in the castration range is no more than 3 months. 4. eastern cooperative oncology group (ecog) physical condition score ≤ 1. 5. patients must have adequate hematologic function, hepatic function and renal function. 6. patients must participate voluntarily and sign an informed consent form(icf), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. patients must be willing to obey the prohibitions and restrictions specified in the research protocol. 7. fertile patients must be willing to use highly effective contraception during the study period. exclusion criteria: 1. patients with prostatic histopathology exhibiting neuroendocrine, small cell, or sarcomatoid features. 2. the researchers assessed the primary lesion as unresectable. 3. patients who had previously received androgen deprivation therapy (including medical or surgical castration) for more than 3 months, or had undergone focal therapy for prostate cancer, or had received radiotherapy or chemotherapy for prostate cancer. 4. patients with severe or uncontrolled underlying diseases who could not tolerate surgery or radiotherapy. 5. patients with new york heart association (nyha) class iii/iv congestive heart failure, unstable angina, or a history of myocardial infarction within the past 6 months. 6. uncontrolled severe hypertension, persistently uncontrolled diabetes, oxygen-dependent pulmonary disease, chronic liver disease, or hiv infection. 7. within the past 5 years, having had other malignant tumors except for prostate cancer, with the exception of cured basal or squamous cell skin cancer. 8. suffering from mental illness, mental disability, or being incapable of providing informed consent.

Keywords: metastatic prostate cancer radiotherapy prostatectomy
short-term effect of rho-kinase inhibitor on retinal circulation

Conditions: Glaucoma, Open-Angle

Summary: investigate changes in optical coherence tomography angiography of the optic nerve and macula following topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution.


Eligibility criteria:
inclusion criteria: * normal ocular health exclusion criteria: * females who are or may be pregnant or who are nursing * uncontrolled hypertension * allergy to netarsudil or latanoprost
cross-linked hyaluronan gel reduces rectal toxicity due to radiation therapy for prostate cancer

Conditions: Prostate Cancer

Summary: the primary purpose of this study is to determine if cross-linked hyaluronan gel reduces the dose of radiation delivered to the rectum and the rectal toxicity of radiotherapy for localized prostate cancer.

the main risk associated with transperineal injection of cross-linked hyaluronan gel into the anterior perirectal fat is infection. prophylactic antibiotics will be given, resulting in a \<5% risk. another possible risk (\<5%) is an allergic reaction such as itching. patients who are allergic to avian products will be excluded from the study. tenderness and pain at the injection site are possible. bleeding, bruising, redness, or discoloration or the formation of a bump (granuloma) or scar (keloid) at the injection site is also possible. embolization of cross-linked hyaluronan gel through the blood is a potential, rare complication if the gel is injected into a blood vessel rather than into fat. prada et al. did not see any side effects related to the injection or the material itself in 27 patients based on a mean follow-up of 13 months (range: 9-22 months). patients did not complain of pain, tenesmus, rectal pressure, or a sensation of rectal filling. risks beyond 22 months are not well defined. potential benefits of cross-linked hyaluronan gel include fewer rectal complications due to radiotherapy for early-stage prostate cancer.

Eligibility criteria:
inclusion criteria: 1. histologically-confirmed adenocarcinoma of the prostate, clinical stage t1c-t2c, nx, n0, m0. 2. nodes determined to be negative by imaging methods will be classified as nx. only nodes determined to be negative by surgical sampling will be classified as n0. 3. prostate cancer biopsy grading by gleason score classification is mandatory. 4. no prior pelvic radiotherapy. induction hormonal therapy for less than or equal to 6 months is acceptable. 5. prostate volume by trus \< 50 cc prior to hdr brachytherapy. 6. prostate specific antigen (psa) less than or equal to 30 ng/ml. 7. patient has provided informed consent. exclusion criteria: 1. clinical stage t3 or t4. 2. clinical evidence of lymph node involvement (n1). 3. clinical evidence of distant metastases (m1). 4. radical surgery for carcinoma of the prostate. 5. allergy to avian products. 6. significant mental, medical, or physical impairment. 7. prisoners. 8. employees of the cancer center of irvine.

Keywords: prostate cancer cross-linked hyaluronan gel hylaform rectal toxicity
an app to aid in transitioning off opioid medication

Conditions: Opiate Use Disorder; Opiate Withdrawal Syndrome

Summary: the investigators propose to develop a smartphone app (called betteroff) that will help patients manage opioid withdrawal during opioid medication taper and detoxification. the betteroff smartphone intervention will be a resource patients can access anytime and anywhere. if the betteroff intervention were to be effective in helping patients discontinue opioid medication, it could be integrated into the standard of care of office-based clinical practices, as well as substance use programs, thereby having a substantial public health impact.

many of the growing number of patients prescribed long-term opioid medication (for a variety of reasons including a history of illicit opioid use or management of chronic pain) will express an interest in discontinuing medication. however, many patients, physically dependent on opioids, fear the withdrawal symptoms that inevitably occur with opioid medication discontinuation and will experience a decrease in their self-efficacy for abstinence at the end of a taper. as a result, tapering is often slow and done hesitantly, and relapse rates after an opioid taper are high and associated with broad consequences, including significant negative physical, mental, and social problems. even with optimal tapering protocols, patients need novel approaches to manage the discontinuation of opiate agonist treatment. given this important gap in opioid treatment delivery, we propose to develop a theoretically-driven, smartphone-delivered intervention (better off app) to help patients effectively manage the experience of opioid medication discontinuation.

Eligibility criteria:
inclusion criteria: * between 18-65 years of age; * currently receiving opioid medication; * interesting in discontinuing opioid medication * has a smartphone exclusion criteria: * non-english speaking.
effect of ifn-γ on innate immune cells

Conditions: Chronic Granulomatous Disease

Summary: the investigators hypothesize that neutrophils and monocytes developed under the influence of interferon- gamma-1b (ifn-γ-1b, actimmune\*) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. the investigators will evaluate the effects of ifn-γ in healthy human subjects in vivo on gene expression, biologic activity markers, and functional activity of myeloid cells in single dose studies and in steady state studies.

named for their potent ability to interfere and protect against viral infections, interferons (ifns) have many regulatory effects on the immune system.1 of the members of the two classes of these compounds, ifn-γ has the most diverse and powerful immune effects. studies have mostly evaluated ifn-γ interactions with cells of adaptive immunity, including macrophages and lymphocytes. effects on innate immunity, particularly polymorphonuclear leukocytes or neutrophils and monocytes are less well studied. however, investigations have suggested that ifn-γ may be involved in signal transduction, gene expression, the respiratory burst and neutrophil nadph oxidase (nox2) activity, phagocytosis, motility, microbicidal activity, and apoptosis. not all of these functions are enhanced by ifn-γ; but the clinical use of this cytokine has been driven, in part by these results. for example, the primary motivation for initiating investigation of its beneficial clinical effects in chronic granulomatous disease (cgd) was its effects on nox2 activity.2 most data in this area was based on studies using differentiated neutrophils from peripheral blood.1 however, the phenotype of neutrophils developed under the influence of this cytokine, not just changes expressed by exposure of differentiated cells to ifn-γ, is critical to understanding the physiologic effects of ifn-γ and the broad applications for its use in treatment of a range of human diseases. to expand their understanding of the role of ifn-γ in the development and functional integrity of the neutrophil, the investigators have completed a series of studies with plb-985 cells in an in vitro culture system of myeloid cells. in this proposal, the investigators will evaluate innate immune activation and phagocyte function in healthy adult volunteers who are receiving ifn-γ.

Eligibility criteria:
inclusion criteria: 1. healthy adults over the age of 18 years up to 60 years. 2. at time of screening subject is well and healthy; 3. acute infections resolved; 4. subject off treatment medications; 5. no diagnosis of chronic conditions or active health care issues for which the subject is actively followed by a health care provider or is on chronic medications. 6. non-prescription medications for mild inter-current illnesses will be allowed at the discretion of the principal investigator. exclusion criteria: 1. pregnancy. 2. history of current infection; 3. two weeks from most recent intercurrent infection; 4. history of recurrent infections or immunodeficiency.

Keywords: interferon-gamma innate immunity
postoperative pain and healing in teeth treated with gentlewave or endoactivator

Conditions: Symptomatic Irreversible Pulpitis; Apical Periodontitis

Summary: patients with painful molars will be randomly assigned to 2 different groups: gentlewave and endoactivator. the root canals will be completed using identical protocols except in the mode of delivery and activation of irrigation (using either the gentlewave or endoactivator). postoperative pain and pain pill consumption will be measured for the 4 days following their root canal using a visual analog scale and pain pill log, respectively. the alternative hypothesis is that patients undergoing treatment using the gentlewave will experience less pain postoperatively and will consume fewer pain pills. a 12-month follow up with exam and radiographs will be completed to evaluate healing.


Eligibility criteria:
inclusion criteria: • adults, able to provide informed consent, with restorable symptomatic molars reporting preoperative pain ≥20mm on a 100mm visual analog scale (vas) during the previous 24 hours. exclusion criteria: * minors * pregnant women * prisoners * persons unable to adequately provide informed consent * non-restorable teeth * patients unable to sit in the dental chair for 3 hours * patients with compromised cardiac health requiring less than .08mg epinephrine * patients with a pacemaker * patients where ibuprofen and acetaminophen are contraindicated * patients unable to swallow pills * patients with pain originating somewhere other than the tooth in question * patients having taken analgesics within previous 6 hours
korean college of rheumatology biologics and targeted therapy registry

Conditions: Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis

Summary: we established a nationwide biologics and targeted synthetic dmards registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving biologics or targeted synthetic dmards. as this registry is to observe the "real world" use of anti-rheumatic treatments under routine clinical practice, no hypothesis to prove is planned.

this registry is a multi-center, prospective, observational program that will gather and analyze data on patients being treated with biologics and targeted synthetic dmards in korea. in contrast to a controlled clinical trial, there is no imposed experimental intervention and solely the patients' physicians will determine the patient's treatment. thus, the data captured and reported in this registry will reflect a "real world" approach to the treatment with biologics or targeted synthetic dmards. there will be no additional visit or laboratory test done outside the routine clinical practice. the selection of the agent, dosing, and treatment duration is determined by the investigator. informed consent will be obtained from the patient prior to the collection of any data.

Eligibility criteria:
inclusion criteria: * patients diagnosed with ra, as or psa * ra deemed by their rheumatologist to require treatment with a biologic or targeted synthetic dmards or a conventional dmard(s) * as or psa patients who are to initiate, restart or switch to a biologic agent or a targeted synthetic dmard * patients who provide a written consent of participating in this registry (data collection and review). exclusion criteria: * ra, as, psa patients who are already on biologics or targeted synthetic dmards upon screening

Keywords: rheumatiod arhthritis ankylosing spondylitis psoriatic arthritis biologic agents cohort studies small molecule agents
church-based intervention to improve blood pressure in african americans

Conditions: Hypertension

Summary: this is a 12-month behavioral cluster-randomized trial testing a church-based intervention to reduce blood pressure in african americans with uncontrolled blood pressure.


Eligibility criteria:
inclusion criteria: churches: * at least 75 members and ability to recruit 15 study participants * predominantly african american congregants participants: * age 18 or older * has blood pressure readings with uncontrolled blood pressure, defined as exceeding the blood thresholds for initiation of antihypertensive medication according to the 2017 american college of cardiology/ american heart association (acc/aha) guidelines. - the thresholds are 140/90 for the general population \< 65 years old, and 130/80 for individuals ≥ 65 or with diabetes, chronic kidney disease, or high cardiovascular risk (self-report of prior diagnosis of myocardial infarction, coronary heart disease, stroke or heart failure) * attends church (virtually or in-person) at least once per month * able to attend weekly zoom meetings * consents and completes all baseline assessments exclusion criteria: churches: • pastor unwilling to conduct bible study participants: * unable to make dietary changes due to lack of control over their food source (i.e., eat meals at shelter, nursing home) * has a medical condition that prohibits or severely restricts ability to eat vegetables (i.e., renal disease, crohn's disease) * has a medical condition with an uncertain 6-month prognosis * inability to give informed consent (i.e., cognitive impairment, does not speak englis * plans to move within the 6 months following enrollment * participated in prior alive intervention * member of household participating in another church